Study identifies patients who benefit most from dinutuximab-based immunotherapy
Using data from a randomized phase III clinical trial of neuroblastoma patients (treated with or without immunotherapy) performed by the Children’s Oncology Group, researchers from the University of Wisconsin School of Medicine and Public Health found that a subset of patients, identified by the presence of a certain set of genes, were more likely to benefit from the immunotherapy than those patients that did not have that set of genes.